

Patrice Viens

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7904362/patrice-viens-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

154
papers

12,608
citations

47
h-index

111
g-index

193
ext. papers

14,130
ext. citations

5.8
avg, IF

5.47
L-index

#	Paper	IF	Citations
154	Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC.. <i>Npj Breast Cancer</i> , 2022 , 8, 12	7.8	0
153	Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study. <i>Bone Marrow Transplantation</i> , 2021 ,	4.4	
152	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial. <i>Genome Medicine</i> , 2021 , 13, 87	14.4	8
151	A study of elite sport-inspired coaching for patients after allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2755-2762	4.4	
150	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. <i>Onc Immunology</i> , 2021 , 10, 1929724	7.2	4
149	REBOUND "Trained to live again": The practice of great Olympic coaches improves and enhances the quality of life of cancer patients in remission after hematopoietic stem cell allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2020 , 55, 997-999	4.4	2
148	NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers. <i>Molecular Oncology</i> , 2020 , 14, 504-519	7.9	13
147	Stem Cells Inhibition by Bevacizumab in Combination with Neoadjuvant Chemotherapy for Breast Cancer. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	2
146	A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases. <i>Cancers</i> , 2019 , 11,	6.6	17
145	A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers. <i>Cancers</i> , 2019 , 11,	6.6	1
144	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. <i>Cancers</i> , 2019 , 11,	6.6	99
143	High Response to Cetuximab in a Patient With -Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-8	3.6	1
142	Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 560-567	9.7	137
141	Safety and efficacy of eribulin for "real-world" older patients with metastatic breast cancer. <i>Journal of Geriatric Oncology</i> , 2018 , 9, 281-283	3.6	12
140	Development of parallel reaction monitoring (PRM)-based quantitative proteomics applied to HER2-Positive breast cancer. <i>Oncotarget</i> , 2018 , 9, 33762-33777	3.3	13
139	Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2018 , 50, 1226-1237	5.2	8
138	The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1383-1391	8.7	23

137	Marketing Authorization Procedures for Advanced Cancer Drugs: Exploring the Views of Patients, Oncologists, Healthcare Decision Makers, and Citizens in France. <i>Medical Decision Making</i> , 2017 , 37, 555-566	2.5	3
136	The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?. <i>Expert Review of Anticancer Therapy</i> , 2017 , 17, 593-606	3.5	1
135	Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106). <i>European Journal of Cancer</i> , 2017 , 79, 166-175	7.5	4
134	A scoring system to guide the decision for a new systemic treatment after at least two lines of palliative chemotherapy for metastatic cancers: a prospective study. <i>Supportive Care in Cancer</i> , 2017 , 25, 2715-2722	3.9	4
133	Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2017 , 28, 769-776	10.3	32
132	PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer. <i>European Journal of Cancer</i> , 2017 , 86, 28-36	7.5	35
131	Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. <i>Annals of Oncology</i> , 2017 , 28, 103-109	10.3	40
130	Abstract S3-01: IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by NEOadjuvant chemotherapy 2017 ,		5
129	MARCKS protein overexpression in inflammatory breast cancer. <i>Oncotarget</i> , 2017 , 8, 6246-6257	3.3	21
128	Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory locally advanced breast cancers. <i>Oncotarget</i> , 2017 , 8, 66019-66032	3.3	7
127	SPAG5: the ultimate marker of proliferation in early breast cancer?. <i>Lancet Oncology, The</i> , 2016 , 17, 863-865	8.5	9
126	Contribution of FDG PET/CT for the Optimization of the Management of Additional Lesions Detected on Local Staging Breast MRI. <i>American Journal of Roentgenology</i> , 2016 , 206, 891-900	5.4	6
125	Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2016 , 17, 600-11	21.7	35
124	Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis. <i>Familial Cancer</i> , 2016 , 15, 497-506	3	5
123	A Phase I Trial of High-Dose Chemotherapy Combining Topotecan plus Cyclophosphamide with Hematopoietic Stem Cell Transplantation for Ovarian Cancer: The ITOV 01bis Study. <i>Chemotherapy</i> , 2016 , 61, 15-22	3.2	1
122	Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation. <i>European Journal of Cancer</i> , 2016 , 57, 118-26	7.5	4
121	Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study. <i>Oncotarget</i> , 2016 , 7, 79428-79441	3.3	8
120	MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. <i>Oncotarget</i> , 2016 , 7, 18531-40	3.3	31

119	Comparative genomic analysis of primary tumors and metastases in breast cancer. <i>Oncotarget</i> , 2016 , 7, 27208-19	3.3	53
118	Heterogeneity of metastatic pancreatic adenocarcinoma: Lung metastasis show better prognosis than liver metastasis-a case control study. <i>Oncotarget</i> , 2016 , 7, 45649-45655	3.3	16
117	Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study. <i>Journal of Cancer</i> , 2016 , 7, 2077-2084	4.5	4
116	Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1082-6	4.4	12
115	Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis. <i>Breast</i> , 2016 , 27, 8-14	3.6	3
114	METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors. <i>Anticancer Research</i> , 2016 , 36, 293-9	2.3	7
113	Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. <i>American Journal of Pathology</i> , 2015 , 185, 1022-32	5.8	35
112	UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. <i>Annals of Oncology</i> , 2015 , 26, 1692-7	10.3	13
111	Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study. <i>BMC Cancer</i> , 2015 , 15, 697	4.8	2
110	Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study. <i>International Journal of Gynecological Cancer</i> , 2015 , 25, 815-22	3.5	25
109	Prognostic and predictive value of PDL1 expression in breast cancer. <i>Oncotarget</i> , 2015 , 6, 5449-64	3.3	313
108	Overexpression of the Promigratory and Prometastatic PTK7 Receptor Is Associated with an Adverse Clinical Outcome in Colorectal Cancer. <i>PLoS ONE</i> , 2015 , 10, e0123768	3.7	27
107	PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. <i>Oncotarget</i> , 2015 , 6, 13506-19	3.3	87
106	Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. <i>Clinical Cancer Research</i> , 2015 , 21, 1298-304	12.9	43
105	Circulating tumor cells (CTC) and pathological complete response (pCR) as independent prognostic factors in inflammatory breast cancer (IBC) in a pooled analysis of two multicentre phase II trials (BEVERLY 1 & 2) of neoadjuvant chemotherapy combined with bevacizumab.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 108-108	2.2	1
104	A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. <i>Oncotarget</i> , 2015 , 6, 746-54	3.3	16
103	Effect of high MMP2 and low MMP9 baseline serum levels on outcome in patients with HER2-positive inflammatory breast cancer (IBC) treated with bevacizumab (BEV)- and trastuzumab (TRA)-based neoadjuvant chemotherapy (NAC) in the BEVERLY 2 study.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 600-600	2.2	
102	Pancreatic neuroendocrine tumors (pNET) in adolescent and young adult (AYA) population: A multi-institutional study of characteristics and outcomes.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15173-e15173	2.2	2

101	Pancreatic adenocarcinoma in adolescent and young adults (18-44): Characteristics and clinical outcomes from Canada and France.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15215-e15215	2.2	
100	Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. <i>Annals of Oncology</i> , 2014 , 25, 358-65	10.3	65
99	Assessment of prognostic scores in brain metastases from breast cancer. <i>Neuro-Oncology</i> , 2014 , 16, 421-8		15
98	Clinical development of mTOR inhibitors in breast cancer. <i>Breast Cancer Research</i> , 2014 , 16, 203	8.3	41
97	EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. <i>Cancer Letters</i> , 2014 , 355, 70-5	9.9	30
96	Genomic profiling of inflammatory breast cancer: a review. <i>Breast</i> , 2014 , 23, 538-45	3.6	40
95	Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. <i>PLoS ONE</i> , 2014 , 9, e81843	3.7	42
94	Carcinomatous myelitis and meningitis after a squamous cell carcinoma of the lip. <i>Case Reports in Oncology</i> , 2014 , 7, 33-8	1	2
93	Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. <i>Molecular Cancer</i> , 2014 , 13, 228	42.1	73
92	Prognostic impact of the combination of erythropoiesis-stimulating agents to cancer treatment: literature review. <i>Supportive Care in Cancer</i> , 2013 , 21, 2359-69	3.9	2
91	ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program. <i>Cancer Research</i> , 2013 , 73, 7290-300	10.1	98
90	BetaHCG secretion by a pulmonary adenocarcinoma. <i>World Journal of Surgical Oncology</i> , 2013 , 11, 228	3.4	8
89	Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. <i>Clinical Cancer Research</i> , 2013 , 19, 4685-96	12.9	99
88	Genomic and expression analysis of microdissected inflammatory breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 761-72	4.4	41
87	Prediction of BRCA1 germ-line mutation status in patients with breast cancer using histoprognosis grade, MS110, Lys27H3, vimentin, and KI67. <i>Pathobiology</i> , 2013 , 80, 219-27	3.6	10
86	Breast cancer patients' views on the use of genomic testing to guide decisions about their postoperative chemotherapy. <i>Public Health Genomics</i> , 2013 , 16, 110-7	1.9	6
85	Difference in therapeutic response between basal and nonbasal triple-negative breast cancers. <i>Oncologist</i> , 2013 , 18, 1060-1	5.7	2
84	Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. <i>Annals of Oncology</i> , 2013 , 24, 1231-8	10.3	53

83	Young breast cancer patients' involvement in treatment decisions: the major role played by decision-making about surgery. <i>Psycho-Oncology</i> , 2013 , 22, 2546-56	3.9	16
82	Complementary or alternative medicine as possible determinant of decreased persistence to aromatase inhibitor therapy among older women with non-metastatic breast cancer. <i>PLoS ONE</i> , 2013 , 8, e81677	3.7	16
81	Tailored chemotherapy based on tumour gene expression analysis: breast cancer patients' misinterpretations and positive attitudes. <i>European Journal of Cancer Care</i> , 2012 , 21, 242-50	2.4	22
80	Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. <i>Lancet Oncology, The</i> , 2012 , 13, 420-32	21.7	52
79	Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study. <i>Lancet Oncology, The</i> , 2012 , 13, 375-84	21.7	134
78	Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. <i>European Respiratory Journal</i> , 2012 , 39, 172-9	13.6	31
77	Self-reported cognitive impairment after breast cancer treatment in young women from the ELIPPSE40 cohort: the long-term impact of chemotherapy. <i>Breast Journal</i> , 2012 , 18, 406-14	1.2	15
76	Patients' regrets after participating in a randomized controlled trials depended on their involvement in the decision making. <i>Journal of Clinical Epidemiology</i> , 2012 , 65, 635-42	5.7	20
75	Early discontinuation of tamoxifen intake in younger women with breast cancer: is it time to rethink the way it is prescribed?. <i>European Journal of Cancer</i> , 2012 , 48, 1939-46	7.5	66
74	Association of carcinoid tumor and low grade glioma. <i>World Journal of Surgical Oncology</i> , 2012 , 10, 236	3.4	1
73	Microarray Analysis Identifies an Expression Signature for Inflammatory Breast Cancer 2012 , 243-258		
72	Are there candidates for high-dose chemotherapy in ovarian carcinoma?. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012 , 31, 87	12.8	5
71	8q24 Cancer risk allele associated with major metastatic risk in inflammatory breast cancer. <i>PLoS ONE</i> , 2012 , 7, e37943	3.7	27
70	Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer. <i>PLoS ONE</i> , 2012 , 7, e43409	3.7	2
69	Mevalonate metabolism regulates Basal breast cancer stem cells and is a potential therapeutic target. <i>Stem Cells</i> , 2012 , 30, 1327-37	5.8	97
68	Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 1035-47	4.4	12
67	Transparency in the presentation of trial results may not increase patients' trust in medical researchers. <i>Clinical Trials</i> , 2012 , 9, 90-3	2.2	2
66	Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. <i>Bone Marrow Transplantation</i> , 2012 , 47, 549-55	4.4	34

65	BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. <i>Annals of Oncology</i> , 2012 , 23, 2799-2805	10.3	156
64	Biomarker discovery, development, and implementation in France: a report from the French National Cancer Institute and cooperative groups. <i>Clinical Cancer Research</i> , 2012 , 18, 1555-60	12.9	25
63	Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?. <i>Annals of Oncology</i> , 2012 , 23, 714-721	10.3	40
62	Angiogenesis and Lymphangiogenesis in IBC: Insights from a Genome-Wide Gene Expression Profiling Study 2012 , 225-242		
61	Recent trends in epidemiology of brain metastases: an overview. <i>Anticancer Research</i> , 2012 , 32, 4655-62	2.3	179
60	Peritumoural vascular invasion: a major determinant of triple-negative breast cancer outcome. <i>European Journal of Cancer</i> , 2011 , 47, 1537-45	7.5	22
59	Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. <i>Breast Cancer Research</i> , 2011 , 13, R109	8.3	18
58	A gene expression signature identifies two prognostic subgroups of basal breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 407-20	4.4	192
57	Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 363-73	4.4	7
56	Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 273-81	4.4	58
55	Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011 , 129, 401-9	4.4	1
54	L'après cancer : mise en place du plan personnalisé de l'après cancer (PPAC). <i>Oncologie</i> , 2011 , 13, 271-276	1	
53	Kinome expression profiling and prognosis of basal breast cancers. <i>Molecular Cancer</i> , 2011 , 10, 86	42.1	40
52	Full access to medical records does not modify anxiety in cancer patients: results of a randomized study. <i>Cancer</i> , 2011 , 117, 4796-804	6.4	24
51	Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011 , 80, 483-91	4	55
50	A seven-gene prognostic model for platinum-treated ovarian carcinomas. <i>British Journal of Cancer</i> , 2011 , 105, 304-11	8.7	28
49	International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. <i>Annals of Oncology</i> , 2011 , 22, 515-523	10.3	321
48	PD03-01: An Integrated Analysis of Three Distinct IBC/nIBC Affymetrix Gene Expression Data Sets Further Unveils the Molecular Biology of IBC. 2011 ,		2

47	Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. <i>Journal of Clinical Investigation</i> , 2011 , 121, 3609-22	15.9	391
46	BAYPAN study: A double-blind, phase III randomized trial of gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with advanced pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4028-4028	2.2	7
45	High-resolution comparative genomic hybridization of inflammatory breast cancer and identification of candidate genes. <i>PLoS ONE</i> , 2011 , 6, e16950	3.7	50
44	Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. <i>Anticancer Research</i> , 2011 , 31, 1079-86	2.3	12
43	Resection of residual masses after chemotherapy for advanced non-seminomatous germ cell tumours, a monocentric analysis of pre-operative prognosticators. <i>European Journal of Cancer Care</i> , 2010 , 19, 827-32	2.4	3
42	Participants' uptake of clinical trial results: a randomised experiment. <i>British Journal of Cancer</i> , 2010 , 102, 1081-4	8.7	15
41	Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study. <i>Annals of Oncology</i> , 2010 , 21, 1448-1454	10.3	13
40	Impact of lapatinib monotherapy on QOL and pain symptoms in patients with HER2+ relapsed or refractory inflammatory breast cancer. <i>Current Medical Research and Opinion</i> , 2010 , 26, 1065-73	2.5	9
39	Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 45-55	12.9	570
38	Loss, mutation and deregulation of L3MBTL4 in breast cancers. <i>Molecular Cancer</i> , 2010 , 9, 213	42.1	38
37	Genome profiling of ERBB2-amplified breast cancers. <i>BMC Cancer</i> , 2010 , 10, 539	4.8	114
36	Low-grade extraskeletal osteosarcoma of the chest wall: case report and review of literature. <i>BMC Cancer</i> , 2010 , 10, 645	4.8	25
35	Platelet recovery and transfusion needs after reduced intensity conditioning allogeneic peripheral blood stem cell transplantation. <i>Experimental Hematology</i> , 2010 , 38, 55-60	3.1	13
34	Gene expression profiling of inflammatory breast cancer. <i>Cancer</i> , 2010 , 116, 2783-93	6.4	42
33	Systemic therapy of inflammatory breast cancer from high-dose chemotherapy to targeted therapies: the French experience. <i>Cancer</i> , 2010 , 116, 2829-36	6.4	14
32	Allogeneic hematopoietic stem cell transplantation in ovarian cancer-the EBMT experience. <i>International Journal of Cancer</i> , 2010 , 127, 1446-52	7.5	7
31	Prescribers' attitudes toward elderly breast cancer patients. Discrimination or empathy?. <i>Critical Reviews in Oncology/Hematology</i> , 2010 , 75, 138-50	7	37
30	How different are luminal A and basal breast cancers?. <i>International Journal of Cancer</i> , 2009 , 124, 1338-48.5	48.5	46

29	Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. <i>Cancer Research</i> , 2009 , 69, 1302-13	10.1	938
28	Docetaxel first-line therapy in HER2-negative advanced breast cancer: a cohort study in patients with prospectively determined HER2 status. <i>Anti-Cancer Drugs</i> , 2009 , 20, 946-52	2.4	3
27	Defining the molecular biology of inflammatory breast cancer. <i>Seminars in Oncology</i> , 2008 , 35, 41-50	5.5	47
26	Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. <i>Cancer Research</i> , 2008 , 68, 767-76	10.1	86
25	Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. <i>Molecular and Cellular Proteomics</i> , 2008 , 7, 1420-33	7.6	62
24	How basal are triple-negative breast cancers?. <i>International Journal of Cancer</i> , 2008 , 123, 236-40	7.5	336
23	Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation. <i>Haematologica</i> , 2007 , 92, 1004-6	6.6	64
22	Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3407-14	2.2	331
21	Integrated profiling of basal and luminal breast cancers. <i>Cancer Research</i> , 2007 , 67, 11565-75	10.1	232
20	ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. <i>Cell Stem Cell</i> , 2007 , 1, 555-67	18	3079
19	Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. <i>BMC Cancer</i> , 2006 , 6, 245	4.8	100
18	Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5664-71	2.2	444
17	Gene expression profiling and clinical outcome in breast cancer. <i>OMICS A Journal of Integrative Biology</i> , 2006 , 10, 429-43	3.8	47
16	Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. <i>Cancer Research</i> , 2006 , 66, 4636-44	10.1	235
15	Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. <i>Cancer Research</i> , 2005 , 65, 2170-8	10.1	186
14	Protein expression profiling identifies subclasses of breast cancer and predicts prognosis. <i>Cancer Research</i> , 2005 , 65, 767-79	10.1	141
13	Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. <i>Cancer Research</i> , 2004 , 64, 8558-65	10.1	155
12	Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. <i>Oncogene</i> , 2004 , 23, 1377-91	9.2	265

11	Identification and validation of an ERBB2 gene expression signature in breast cancers. <i>Oncogene</i> , 2004 , 23, 2564-75	9.2	101
10	Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'. <i>Journal of Pathology</i> , 2004 , 202, 265-73	9.4	150
9	Comparative multi-methodological measurement of ERBB2 status in breast cancer. <i>Journal of Pathology</i> , 2004 , 202, 286-98	9.4	58
8	Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. <i>Blood</i> , 2004 , 103, 435-41	2.2	111
7	High-dose chemotherapy for breast cancer: the French PEGASE experience. <i>Cancer Control</i> , 2003 , 10, 42-7	2.2	69
6	Loss of FHIT protein expression is a marker of adverse evolution in good prognosis localized breast cancer. <i>International Journal of Cancer</i> , 2003 , 107, 854-62	7.5	16
5	Can sequential administration minimise the cost of high dose chemotherapy? An economic assessment in inflammatory breast cancer. <i>Pharmacoeconomics</i> , 2003 , 21, 807-18	4.4	1
4	Gene expression profiles of poor-prognosis primary breast cancer correlate with survival. <i>Human Molecular Genetics</i> , 2002 , 11, 863-72	5.6	90
3	Distinct and complementary information provided by use of tissue and DNA microarrays in the study of breast tumor markers. <i>American Journal of Pathology</i> , 2002 , 161, 1223-33	5.8	133
2	High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment?. <i>Journal of Clinical Oncology</i> , 2000 , 18, 754-64	2.2	55
1	Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma. <i>Cancer</i> , 1999 , 85, 2190-2199	6.4	32